BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 186] [Cited by in F6Publishing: 148] [Article Influence: 46.5] [Reference Citation Analysis]
Number Citing Articles
1 Pigneur B, Ruemmele FM. A critical review of adalimumab for the treatment of moderate-to-severe active ulcerative colitis in children. Expert Review of Gastroenterology & Hepatology 2022. [DOI: 10.1080/17474124.2022.2149489] [Reference Citation Analysis]
2 Zambrano-sánchez R, Alvarez-mena P, Hidalgo D, Liquitay CME, Franco JVA, Vernooij RWM, Simancas-racines D, Viteri-garcía A, Montesinos-guevara C. Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of inflammatory bowel disease using the AGREE II instrument: a systematic review. BMC Gastroenterol 2022;22:447. [DOI: 10.1186/s12876-022-02539-9] [Reference Citation Analysis]
3 Burgess CJ, Jackson R, Chalmers I, Russell RK, Hansen R, Scott G, Henderson P, Wilson DC. The inexorable increase of biologic exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study. Aliment Pharmacol Ther 2022;56:1453-9. [PMID: 36196524 DOI: 10.1111/apt.17217] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Guinness F, Rodriguez-herrera A. Central venous sinus thrombosis in a young girl with ulcerative colitis. BMJ Case Rep 2022;15:e249904. [DOI: 10.1136/bcr-2022-249904] [Reference Citation Analysis]
5 Ferreiro-iglesias R, Piqueras M, Ricart E, Sempere L, Roca M, Martín de Carpi J, Bentitez O, Zabana Y, Mañosa M, Rodríguez-moranta F, Barreiro-de Acosta M. Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel Disease patients. Gastroenterología y Hepatología (English Edition) 2022. [DOI: 10.1016/j.gastre.2022.03.004] [Reference Citation Analysis]
6 Radygina TV, Illarionov AS, Petrichuk SV, Kuptsova DG, Kurbatova OV, Fisenko AP, Potapov AS, Semikina EL, Anushenko AO. The use of drug monitoring of infliximab and adalimumab to optimize the treatment of inflammatory bowel diseases in children. RPJ 2022;25:313-320. [DOI: 10.46563/1560-9561-2022-25-5-313-320] [Reference Citation Analysis]
7 Atia O, Shavit-brunschwig Z, Mould DR, Stein R, Matar M, Aloi M, Ledder O, Focht G, Urlep D, Hyams J, Broide E, Weiss B, Levine J, Russell RK, Turner D. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00307-7] [Reference Citation Analysis]
8 Heetmeyer J, Schwerd T. Chronisch-entzündliche Darmerkrankungen. Monatsschr Kinderheilkd 2022. [DOI: 10.1007/s00112-022-01604-7] [Reference Citation Analysis]
9 Choi S, Kim ES, Kwon Y, Kim MJ, Choe YH, Choe BH, Kang B. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent. J Korean Med Sci 2022;37:e282. [PMID: 36163478 DOI: 10.3346/jkms.2022.37.e282] [Reference Citation Analysis]
10 Leiz M, Knorr M, Moon K, Tischler L, Sohrabi K, Cantez S, Däbritz J, de Laffolie J, Berg NVD. Can patient registries contribute to guideline-based healthcare? A retrospective analysis of the CEDATA-GPGE registry for pediatric inflammatory bowel disease.. [DOI: 10.21203/rs.3.rs-1901469/v1] [Reference Citation Analysis]
11 Eshel Fuhrer A, Kammar H, Herzlich J, Sukhotnik I. Transanal ileal pouch anal anastomosis for ulcerative colitis in children and adults: a systematic review and meta-analysis. Pediatr Surg Int. [DOI: 10.1007/s00383-022-05222-y] [Reference Citation Analysis]
12 Chen JR, Mai L, Sun JC, Peng X, Zhang M, Zhi M. Efficacy and safety of low-dose thalidomide combined with mesalazine in the treatment of refractory ulcerative colitis in adults. Gastroenterol Rep (Oxf) 2022;10:goac032. [PMID: 35975242 DOI: 10.1093/gastro/goac032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lee KJ, Choi SY, Lee YM, Kim HW. Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Case-Control Study. Vaccines (Basel) 2022;10:1265. [PMID: 36016153 DOI: 10.3390/vaccines10081265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Alhadab AA, AlMahamed SN, Hassan IE, Hammo AH. The impact of inflammatory bowel diseases on the quality of life of Saudi pediatric patients: A cross-sectional study. Saudi J Gastroenterol 2022. [PMID: 35946259 DOI: 10.4103/sjg.sjg_162_22] [Reference Citation Analysis]
15 Zambrano-sánchez R, Alvarez-mena P, Hidalgo D, Liquitay CME, Franco J, Vernooij RW, Simancas-racines D, Viteri-garcía A, Montesinos-guevara C. Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of Inflammatory Bowel Disease using the AGREE II instrument: A Systematic Review.. [DOI: 10.21203/rs.3.rs-1754875/v1] [Reference Citation Analysis]
16 Martins AL, Fróes RSB, Zago-Gomes MP. Prevalence, phenotype and medication for the pediatric inflammatory bowel disease population of a state in Southeastern Brazil. World J Clin Pediatr 2022; 11(4): 341-350 [DOI: 10.5409/wjcp.v11.i4.341] [Reference Citation Analysis]
17 Yachha SK, Sarma MS, Mohan N, Wadhwa N, Vr NK, Srinivasan R, Shah D, Soans S, Yewale V, Basavaraja G, Parekh BJ. Indian Academy of Pediatrics Consensus Guidelines for Probiotic Use in Childhood Diarrhea. Indian Pediatr 2022;59:543-51. [DOI: 10.1007/s13312-022-2557-7] [Reference Citation Analysis]
18 Schmid F, Chao C, Däbritz J. Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease. IJMS 2022;23:7287. [DOI: 10.3390/ijms23137287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kakiuchi T, Yoshiura M. Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis. Clin Ther 2022:S0149-2918(22)00216-8. [PMID: 35779956 DOI: 10.1016/j.clinthera.2022.06.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Chen Y, Xiao F, Wang Y, Sun M, Teng X. Analysis of the Clinical Efficacy of Infliximab in the Treatment of Steroid-Refractory Ulcerative Colitis in Children. Iran J Pediatr 2022;32. [DOI: 10.5812/ijp-119605] [Reference Citation Analysis]
21 Lund K, Larsen MD, Knudsen T, Kjeldsen J, Nielsen RG, Brage S, Nørgård BM. Physical activity measured by accelerometry in paediatric and young adult patients with inflammatory bowel disease. BMC Gastroenterol 2022;22:290. [PMID: 35672666 DOI: 10.1186/s12876-022-02358-y] [Reference Citation Analysis]
22 De Laffolie J, Ballauff A, Wirth S, Blueml C, Rommel FR, Claßen M, Laaß M, Lang T, Hauer AC; the CEDATA-GPGE Study Group. Occurrence of Thromboembolism in Paediatric Patients With Inflammatory Bowel Disease: Data From the CEDATA-GPGE Registry. Front Pediatr 2022;10:883183. [DOI: 10.3389/fped.2022.883183] [Reference Citation Analysis]
23 Ong WC, Lim MS, Chan E, Lim TCT, Lim TG, Chan W. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol. JGH Open. [DOI: 10.1002/jgh3.12776] [Reference Citation Analysis]
24 Dipasquale V, Cucinotta U, Romano C. Biosimilars in Pediatric IBD: Updated Considerations for Disease Management. BTT 2022;Volume 16:57-66. [DOI: 10.2147/btt.s367032] [Reference Citation Analysis]
25 Nassar R, Waisbourd‐zinman O. Autoimmune liver disease in gastrointestinal conditions. Clinical Liver Disease. [DOI: 10.1002/cld.1223] [Reference Citation Analysis]
26 Fabi M, Filice E, Andreozzi L, Mattesini BE, Rizzello A, Palleri D, Dajti E, Zagari RM, Lanari M. Combination of fecal calprotectin and initial coronary dimensions to predict coronary artery lesions persistence in Kawasaki disease. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-12702-7] [Reference Citation Analysis]
27 Dipasquale V, Lo Presti G, Romano C. Disease phenotype and outcomes of very early-onset inflammatory bowel disease. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.001] [Reference Citation Analysis]
28 Moss JG, Parry CM, Holt RCL, McWilliam SJ. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res 2022;27:61. [PMID: 35488310 DOI: 10.1186/s40001-022-00687-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Légeret C, Furlano R, Köhler H. Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review. Children 2022;9:617. [DOI: 10.3390/children9050617] [Reference Citation Analysis]
30 Ventin-Holmberg R, Höyhtyä M, Saqib S, Korpela K, Nikkonen A, Salonen A, de Vos WM, Kolho KL. The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α. Sci Rep 2022;12:6654. [PMID: 35459927 DOI: 10.1038/s41598-022-10548-7] [Reference Citation Analysis]
31 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]
32 Dipasquale V, Cicala G, Spina E, Romano C. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Front Pharmacol 2022;13:846151. [PMID: 35370732 DOI: 10.3389/fphar.2022.846151] [Reference Citation Analysis]
33 Sathiaseelan M, Bolia R, Barallon R, Alex G, Hardikar W, Rajanayagam J. Impact of ulcerative colitis on liver-related outcomes of children with primary sclerosing cholangitis. J Paediatr Child Health 2022. [PMID: 35373867 DOI: 10.1111/jpc.15954] [Reference Citation Analysis]
34 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
35 Aydın Ö, Kabasakal Çetin A, Samur G. Current Nutritional Therapy Approaches in Pediatric İnflammatory Diseases. jcp 2022;20:103-115. [DOI: 10.4274/jcp.2021.39019] [Reference Citation Analysis]
36 Weber K, Zeißig Y, Haag C, Schmelz R, Pazmandi J, Kalinichenko A, Boztug K, Zeißig S, Aust D, Laass MW, Schuetz C. [Chronic or severe enteropathy and immunodeficiency: be prepared for a rara avis]. Z Gastroenterol 2022. [PMID: 35297030 DOI: 10.1055/a-1709-5024] [Reference Citation Analysis]
37 Devarapalli UV, Sarma MS, Mathiyazhagan G. Gut and liver involvement in pediatric hematolymphoid malignancies. World J Gastrointest Oncol 2022; 14(3): 587-606 [DOI: 10.4251/wjgo.v14.i3.587] [Reference Citation Analysis]
38 Alhalabi MM, Abbas AJ. Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. Annals of Medicine and Surgery 2022;75:103456. [DOI: 10.1016/j.amsu.2022.103456] [Reference Citation Analysis]
39 Śledzińska K, Landowski P, Żmijewski MA, Kamińska B, Kowalski K, Liberek A. Diet, Sun, Physical Activity and Vitamin D Status in Children with Inflammatory Bowel Disease. Nutrients 2022;14:1029. [PMID: 35268001 DOI: 10.3390/nu14051029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 El-lababidi N. Inflammatory bowel disease in children - part 2: treatment and complications. Pediatr pro Praxi 2022;23:13-17. [DOI: 10.36290/ped.2022.002] [Reference Citation Analysis]
41 Kuloglu Z, Çetin F, Urgancı N, Önal Z, Sarı S, Yüksekkaya H, Çaltepe G, Kutluk G, Dumlupinar E; Turkish Inflammatory Bowel Disease Study Group. Nutritional characteristic of children with inflammatory bowel disease in the nationwide inflammatory bowel disease registry from the Mediterranean region. Eur J Clin Nutr 2022. [PMID: 35173290 DOI: 10.1038/s41430-022-01094-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Shentova-eneva R, Yankov I. Pediatric Ulcerative Colitis. Ulcerative Colitis [Working Title] 2022. [DOI: 10.5772/intechopen.102226] [Reference Citation Analysis]
43 Parry CM, Seddon G, Rogers N, Sinha IP, Bracken L, King C, Peak M, Hawcutt DB. Pharmacogenomics and asthma treatment: acceptability to children, families and healthcare professionals. Arch Dis Child. [DOI: 10.1136/archdischild-2021-322396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Szajewska H. Probiotics in Pediatric Gastroenterology. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_54] [Reference Citation Analysis]
45 Calatayud GÁ, Trabazo RL, Marzet CB. Probiotics in Pediatrics. Probiotics for Human Nutrition in Health and Disease 2022. [DOI: 10.1016/b978-0-323-89908-6.00020-0] [Reference Citation Analysis]
46 Pogačar MŠ, Mičetić-turk D, Fijan S. Probiotics: current regulatory aspects of probiotics for use in different disease conditions. Probiotics in the Prevention and Management of Human Diseases 2022. [DOI: 10.1016/b978-0-12-823733-5.00021-0] [Reference Citation Analysis]
47 Rao A, Gokhale R. Ulcerative Colitis. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_30] [Reference Citation Analysis]
48 Tokita K, Shimizu H, Takeuchi I, Shimizu T, Arai K. Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan. Pediatr Gastroenterol Hepatol Nutr 2022;25:461. [DOI: 10.5223/pghn.2022.25.6.461] [Reference Citation Analysis]
49 Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77-81. [PMID: 34966535 DOI: 10.1136/flgastro-2021-101805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Shehab M, Alasfour H, Abdullah I, Alhendi G, Alhadab A, Alfadhli A, Ziyab AH, Battat R. Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study. Front Med 2021;8. [DOI: 10.3389/fmed.2021.801532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Fang SB, Song YQ, Zhang CY, Wang LB. Risk factors for Clostridioides difficile infection in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis. World J Pediatr 2021. [PMID: 34800281 DOI: 10.1007/s12519-021-00486-1] [Reference Citation Analysis]
53 Eindor-Abarbanel A, Healey GR, Jacobson K. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood. Int J Mol Sci 2021;22:12506. [PMID: 34830388 DOI: 10.3390/ijms222212506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Alajmi R, Alabdulhadi M, Alali AA, Shehab M. Tofacitinib for a Child with Refractory Steroid-Dependent Ulcerative Colitis: A Case Report and Review of the Literature. Am J Case Rep 2021;22:e934460. [PMID: 34767543 DOI: 10.12659/AJCR.934460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Bachmann J, Le Thi G, Brückner A, Kalteis AL, Schwerd T, Koletzko S, Lurz E. Epstein-Barr Virus Prevalence at Diagnosis and Seroconversion during Follow-Up in Pediatric Inflammatory Bowel Disease. J Clin Med 2021;10:5187. [PMID: 34768707 DOI: 10.3390/jcm10215187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
57 Kuai XY, Yu SY, Cui XF, Zhao XJ, Mao XQ, Yu Y, Hu T, Zhang HJ, Zhou CL. LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease. Gastroenterol Res Pract 2021;2021:5557357. [PMID: 34621310 DOI: 10.1155/2021/5557357] [Reference Citation Analysis]
58 Larrosa-haro A, Abundis-castro L, Contreras M, Gallo M, Peña-quintana L, Targa Ferreira C, Nacif P, Vázquez-frias R, Bravo S, Muñoz-urribarri A, Mejía-castro M, Orsi M, Amil-díaz J, Busoni V, Cohen-sabban J, Martin-capri F, Zablah R, Rodríguez-guerrero M, Sdepanian V. Tendencia epidemiológica de la enfermedad intestinal inflamatoria en pacientes pediátricos en América Latina: Grupo de Trabajo en Enfermedad Intestinal Inflamatoria, Sociedad Latinoamericana de Gastroenterología, Hepatología y Nutrición Pediátrica (SLAGHNP). Revista de Gastroenterología de México 2021;86:328-334. [DOI: 10.1016/j.rgmx.2020.07.010] [Reference Citation Analysis]
59 Larrosa-Haro A, Abundis-Castro L, Contreras MB, Gallo MJ, Peña-Quintana L, Targa Ferreira CH, Nacif PA, Vázquez-Frías R, Bravo S, Muñoz-Urribarri AB, Mejía-Castro M, Orsi M, Amil-Díaz J, Busoni V, Cohen-Sabban J, Martin-Capri FJ, Zablah R, Rodríguez-Guerrero MG, Sdepanian VL. Epidemiologic trend of pediatric inflammatory bowel disease in Latin America: The Latin American Society for Pediatric Gastroenterology, Hepatology and Nutrition (LASPGHAN) Working Group. Rev Gastroenterol Mex (Engl Ed) 2021;86:328-34. [PMID: 34518143 DOI: 10.1016/j.rgmxen.2021.07.004] [Reference Citation Analysis]
60 Alhalabi M, Eddin KA, Cheha K, Abbas A. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report. Medicine (Baltimore) 2021;100:e27283. [PMID: 34559136 DOI: 10.1097/MD.0000000000027283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 van Hoeve K, Seyed Tabib NS, Dreesen E, Tops S, Hoffman I, Gils A, Ferrante M, Vermeire S. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. J Pediatr 2022;240:150-157.e4. [PMID: 34481805 DOI: 10.1016/j.jpeds.2021.08.079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Martín-masot R, Ortiz Pérez P, Torcuato Rubio E, Blasco Alonso J, Herrador López M, Gallego Fernández C, Navas-lópez VM. The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric Cases. JPGN Reports 2021;2:e100. [DOI: 10.1097/pg9.0000000000000100] [Reference Citation Analysis]
63 Ito N, Takeuchi I, Kyodo R, Hirano Y, Sato T, Usami M, Shimizu H, Shimizu T, Arai K. Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2021;24:357-65. [PMID: 34316470 DOI: 10.5223/pghn.2021.24.4.357] [Reference Citation Analysis]
64 Stallard L, Hussey S. Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-Caveat Emptor. Front Pediatr 2021;9:678132. [PMID: 34249815 DOI: 10.3389/fped.2021.678132] [Reference Citation Analysis]
65 Giorgio V, Blasi E, Rigante D, Guerriero C, De Simone C, Fedele AL, Stella G, Gasbarrini A, Scaldaferri F. Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report. Int J Environ Res Public Health 2021;18:6711. [PMID: 34206410 DOI: 10.3390/ijerph18136711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
66 Bąk-Drabik K, Adamczyk P, Duda-Wrońska J, Dąbrowska-Piechota D, Jarzumbek A, Kwiecień J. Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine. Gastroenterol Res Pract 2021;2021:9970019. [PMID: 34239556 DOI: 10.1155/2021/9970019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Shehab M, Alasfour H, Abdullah I, Alhendi G, Alhadab A, Alfadhli A, Ziyab AH, Battat R. Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-Drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study.. [DOI: 10.1101/2021.06.01.21258121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Socha-Banasiak A, Sputa-Grzegrzółka P, Grzegrzółka J, Pacześ K, Dzięgiel P, Sordyl B, Romanowicz H, Czkwianianc E. Metallothioneins in Inflammatory Bowel Diseases: Importance in Pathogenesis and Potential Therapy Target. Can J Gastroenterol Hepatol 2021;2021:6665697. [PMID: 33987146 DOI: 10.1155/2021/6665697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Dembiński Ł, Stelmaszczyk-Emmel A, Sznurkowska K, Szlagatys-Sidorkiewicz A, Radzikowski A, Banaszkiewicz A. Immunogenicity of cholera vaccination in children with inflammatory bowel disease. Hum Vaccin Immunother 2021;17:2586-92. [PMID: 33794737 DOI: 10.1080/21645515.2021.1884475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Sarbagili-Shabat C, Weiner D, Wardi J, Abramas L, Yaakov M, Levine A. Moderate-to-severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis. J Pediatr Gastroenterol Nutr 2021;72:569-73. [PMID: 33346576 DOI: 10.1097/MPG.0000000000003018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Baranov AA, Namazova-baranova LS, Alexeeva AA, Ambarchian ET, Aslamazyan LK, Astafieva NG, Balykova LA, Belyaeva IA, Bulgakova VA, Vakhlova IV, Vashakmadze ND, Vishneva EA, Getiya EG, Il’ina NI, Kaytukova EV, Kamaltynova EM, Karkashadze GA, Kovtun OP, Komarova EV, Kulichenko TV, Kurbacheva OM, Levina YG, Makarova SG, Murashkin NN, Nesterova YV, Novik GA, Piskunova SG, Popova LY, Privalova TE, Selimzyanova LR, Sergienko NS, Serebryakova EN, Stasiy ED, Tkachenko MA, Turti TV, Ustinova NV, Fedorova OS, Fomina DS, Fugol’ DS, Chemakina DS, Shepeleva IM, Efendieva KE. Amino Acid Formulas in Patients with Gastrointestinal Diseases. Pediatr farmakol 2021;18:38-47. [DOI: 10.15690/pf.v18i1.2222] [Reference Citation Analysis]
72 Choi S, Choi BS, Choe BH, Kang B. Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab. Yeungnam Univ J Med 2021;38:251-7. [PMID: 33601494 DOI: 10.12701/yujm.2020.00878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr 2021;9:634739. [PMID: 33681110 DOI: 10.3389/fped.2021.634739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Orfei M, Gasparetto M, Hensel KO, Zellweger F, Heuschkel RB, Zilbauer M. Guidance on the interpretation of faecal calprotectin levels in children. PLoS One 2021;16:e0246091. [PMID: 33571226 DOI: 10.1371/journal.pone.0246091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis 2021;53:183-9. [PMID: 33132063 DOI: 10.1016/j.dld.2020.10.024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
76 Kolho KL. Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Front Pediatr 2020;8:623689. [PMID: 33520903 DOI: 10.3389/fped.2020.623689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
77 Bowden SA. Bone Densitometry in Children: What Clinicians Need to Know. Endocrine Conditions in Pediatrics 2021. [DOI: 10.1007/978-3-030-52215-5_39] [Reference Citation Analysis]
78 Palazón P, Tarrado X. Laparoscopic Management in Ulcerative Colitis: Staged Proctocolectomy with Ileal Pouch-Anal Anastomosis. Video Atlas of Pediatric Endosurgery (VAPE) 2021. [DOI: 10.1007/978-3-030-58043-8_15] [Reference Citation Analysis]
79 Requeno-jarabo MN. Diarrea y anemia en la infancia: ¿y si es una enfermedad inflamatoria intestinal? Atención Primaria Práctica 2021;3:100076. [DOI: 10.1016/j.appr.2020.100076] [Reference Citation Analysis]
80 Shentova-eneva R, Velikova T. Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New? Gastroenterology Insights 2020;11:58-71. [DOI: 10.3390/gastroent11020009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Jezernik G, Mičetić-Turk D, Potočnik U. Molecular Genetic Architecture of Monogenic Pediatric IBD Differs from Complex Pediatric and Adult IBD. J Pers Med 2020;10:E243. [PMID: 33255894 DOI: 10.3390/jpm10040243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
83 Денисова М. Ф., Букулова Н. Ю.. CLINICAL FORMS OF ULCERATIVE COLITIS AND THEIR FEATURES IN CHILDREN. RS Global - Science Review 2020. [DOI: 10.31435/rsglobal_sr/31102020/7221] [Reference Citation Analysis]
84 Ikeuchi A, Kakiuchi T, Ibi A, Matsuo M. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan. Clin J Gastroenterol 2021;14:146-51. [PMID: 33040281 DOI: 10.1007/s12328-020-01260-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Erős A, Dohos D, Veres G, Tárnok A, Vincze Á, Tészás A, Zádori N, Gede N, Hegyi P, Sarlós P. Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD). BMJ Open 2020;10:e038410. [PMID: 33028560 DOI: 10.1136/bmjopen-2020-038410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Gordon M, Guyatt G. Assessment of Evidence Quality in Inflammatory Bowel Disease Guidance: The Use and Misuse of GRADE. Gastroenterology 2020;159:1209-15. [PMID: 32681924 DOI: 10.1053/j.gastro.2020.06.092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
87 Orlanski-Meyer E, Topf-Olivestone C, Ledder O, Dotan I, Folmer-Hansen L, Kindermann A, Assa A, Kolho KL, Kolaček S, Carroll MW, Strisciuglio C, Aloi M, Hansen R, Navon D, Winter HS, Navas-López VM, de Ridder L, Smets F, Weiss B, Turner D. Outcomes Following Pouch Formation in Paediatric Ulcerative Colitis: A Study From the Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2020;71:346-53. [PMID: 32541197 DOI: 10.1097/MPG.0000000000002805] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Arai K. Very Early-Onset Inflammatory Bowel Disease: A Challenging Field for Pediatric Gastroenterologists. Pediatr Gastroenterol Hepatol Nutr 2020;23:411-22. [PMID: 32953636 DOI: 10.5223/pghn.2020.23.5.411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
89 Diaconescu S, Strat S, Balan GG, Anton C, Stefanescu G, Ioniuc I, Stanescu AMA. Dermatological Manifestations in Pediatric Inflammatory Bowel Disease. Medicina 2020;56:425. [DOI: 10.3390/medicina56090425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Martín-masot R, Ortiz Pérez MP, Ramos Rueda N, Serrano Nieto J, Blasco-alonso J, Navas-lópez VM. Análisis de la determinación de niveles de tiopurínicos en pacientes pediátricos con enfermedad inflamatoria intestinal. Anales de Pediatría 2020;93:34-40. [DOI: 10.1016/j.anpedi.2019.10.005] [Reference Citation Analysis]
91 Martín-masot R, Ortiz Pérez MP, Ramos Rueda N, Serrano Nieto J, Blasco-alonso J, Navas-lópez VM. Laboratory determination of thiopurine levels in paediatric patients with inflammatory bowel disease. Anales de Pediatría (English Edition) 2020;93:34-40. [DOI: 10.1016/j.anpede.2019.10.008] [Reference Citation Analysis]
92 Vriesman MH, Noor N, Koppen IJ, Di Lorenzo C, de Jong JR, Benninga MA. Outcomes after enterostomies in children with and without motility disorders: A description and comparison of postoperative complications. J Pediatr Surg 2020;55:2413-8. [PMID: 32600839 DOI: 10.1016/j.jpedsurg.2020.05.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Krohn K, Pfeifer M, Manzey P, Koletzko S. Chronisch entzündliche Darmerkrankungen – die biopsychosoziale Realität im Kindes- und Jugendalter. Bundesgesundheitsbl 2020;63:839-845. [DOI: 10.1007/s00103-020-03166-z] [Reference Citation Analysis]
94 Conrad MA, Kelsen JR. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies. Curr Gastroenterol Rep 2020;22:36. [PMID: 32542562 DOI: 10.1007/s11894-020-00773-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
95 Souza GN, Draghi PF, Yonamine GH. ORAL AND ENTERAL NUTRITION THERAPY IN INFLAMMATORY BOWEL DISEASES AMONG THE PEDIATRIC POPULATION: A LITERATURE REVIEW. Rev Paul Pediatr 2020;38:e2019032. [PMID: 32520298 DOI: 10.1590/1984-0462/2020/38/2019032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Nikkonen A, Kolho KL. Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatr 2020;109:836-41. [PMID: 31535405 DOI: 10.1111/apa.15026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
97 Buderus S. Endoskopie und histologische Untersuchungen bei chronisch-entzündlichen Darmerkrankungen. Monatsschr Kinderheilkd 2020;168:332-343. [DOI: 10.1007/s00112-020-00862-7] [Reference Citation Analysis]
98 Iheozor-Ejiofor Z, Kaur L, Gordon M, Baines PA, Sinopoulou V, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;3:CD007443. [PMID: 32128794 DOI: 10.1002/14651858.CD007443.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
99 Kaur L, Gordon M, Baines PA, Iheozor-Ejiofor Z, Sinopoulou V, Akobeng AK. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;3:CD005573. [PMID: 32128795 DOI: 10.1002/14651858.CD005573.pub3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
100 Däbritz J. Besonderheiten der Therapie chronisch-entzündlicher Darmerkrankungen im Kindes- und Jugendalter. Monatsschr Kinderheilkd 2020;168:344-51. [DOI: 10.1007/s00112-020-00855-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Magen R, Shaoul R. Alternative & complementary treatment for pediatric inflammatory bowel disease. Transl Pediatr 2019;8:428-35. [PMID: 31993357 DOI: 10.21037/tp.2019.09.02] [Reference Citation Analysis]
102 Rusoniene S, Urbonas V, Avcin T. Extraintestinal Manifestations of Inflammatory Bowel Disease. Periodic and Non-Periodic Fevers 2020. [DOI: 10.1007/978-3-030-19055-2_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut 2020;69:32-41. [PMID: 30979718 DOI: 10.1136/gutjnl-2018-317987] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
104 Keller K. Medikamentöse Therapie der CED bei Kindern und Jugendlichen. Chronisch-entzündliche Darmerkrankungen 2020. [DOI: 10.1007/978-3-662-59104-8_28] [Reference Citation Analysis]
105 Gurram B, Patel AS. Recent advances in understanding and managing pediatric inflammatory bowel disease. F1000Res 2019;8:2097. [DOI: 10.12688/f1000research.19609.1] [Reference Citation Analysis]
106 Kelay A, Tullie L, Stanton M. Surgery and paediatric inflammatory bowel disease. Transl Pediatr 2019;8:436-48. [PMID: 31993358 DOI: 10.21037/tp.2019.09.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Stapersma L, van den Brink G, van der Ende J, Bodelier AG, van Wering HM, Hurkmans PCWM, Mearin ML, van der Meulen-de Jong AE, Escher JC, Utens EMWJ. Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease. Int J Behav Med 2019;26:415-26. [PMID: 31183787 DOI: 10.1007/s12529-019-09791-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
108 Lund K, Larsen MD, Knudsen T, Kjeldsen J, Nielsen RG, Nørgård BM. The impact of anti-TNFα therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015. Aliment Pharmacol Ther 2019;50:1077-85. [PMID: 31579961 DOI: 10.1111/apt.15510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Kim S. Tacrolimus in pediatric ulcerative colitis: does it have a role? Intest Res 2019;17:441-2. [PMID: 31665831 DOI: 10.5217/ir.2019.00124] [Reference Citation Analysis]
110 Velasco Rodríguez-Belvís M, Viada Bris JF, Plata Fernández C, García-Salido A, Asensio Antón J, Domínguez Ortega G, Muñoz Codoceo RA. Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age. Paediatr Child Health 2020;25:286-92. [PMID: 32765164 DOI: 10.1093/pch/pxz070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
111 Turner D. Particularities of IBD Trials in Children. CPD 2019;25:69-72. [DOI: 10.2174/1381612825666190307125511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
112 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
113 Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, Dipasquale V, Paci M, Zuin G, Aloi M, Strisciuglio C, Miele E, Pastore M, Martelossi S, Alvisi P; SIGENP IBD Working Group. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterol J 2019;7:759-66. [PMID: 31316780 DOI: 10.1177/2050640619847592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
114 Hyams JS, Davis Thomas S, Gotman N, Haberman Y, Karns R, Schirmer M, Mo A, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo PA, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis MA, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Saul B, Wang J, Serrano J, Hommel K, Marigorta UM, Gibson G, Xavier RJ, Kugathasan S, Walters T, Denson LA. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019;393:1708-1720. [PMID: 30935734 DOI: 10.1016/s0140-6736(18)32592-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 26.3] [Reference Citation Analysis]
115 Sridhar M, Kesavelu D. Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. Indian Pediatr 2019;56:247-50. [DOI: 10.1007/s13312-019-1509-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Aloi M, Cucchiara S. Acute pancreatitis and azathioprine in paediatric inflammatory bowel disease. The Lancet Child & Adolescent Health 2019;3:131-132. [DOI: 10.1016/s2352-4642(19)30019-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Martín-Masot R, Ortiz Pérez P, Serrano Nieto J, Martínez León M, Pascual Martínez A, Blasco-Alonso J, Navas-López VM. Central Venous Sinus Thrombosis in a Boy With Acute Severe Ulcerative Colitis. Front Pediatr 2019;7:19. [PMID: 30775357 DOI: 10.3389/fped.2019.00019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
118 Zhang L, Wu T. Inflammatory Bowel Disease. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases 2019. [DOI: 10.1007/978-3-030-15573-5_15] [Reference Citation Analysis]
119 Ishige T. Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr 2019;8:16-22. [PMID: 30881894 DOI: 10.21037/tp.2018.12.04] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
120 Buderus S. Aktuelle Aspekte bei der Diagnostik und Therapie von pädiatrischen CED. Gastro-News 2018;5:41-48. [DOI: 10.1007/s15036-018-0505-0] [Reference Citation Analysis]